Bionomics to Trial Drug Against Post-Traumatic Stress Disorder (Bionomics Limited)

(Source: Bionomics Limited) 30cbb2b4-6a94-407a-b184-196dd778cf00.pdf ABN 53 075 582 740 ASX ANNOUNCEMENT 30 June 2016 BIONOMICS TO TRIAL DRUG AGAINST POST-TRAUMATIC STRESS DISORDER Trial to examine effects of Bionomics' drug candidate BNC210 on PTSD No current effective treatments for PTSD 5-10% of population will suffer PTSD at some point ADELAIDE, Australia, 30 June 2016: Bionomics Limited (ASX:BNO; OTCQX:BNOEF), a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of diseases of the central nervous system and cancer, has initiated a Phase II clinical trial with its drug candidate BNC210 in adults suffering Post- Traumatic Stress...